[177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease.

Mercolli, Lorenzo; Mingels, Clemens; Manzini, Giulia; Cumming, Paul; Zeimpekis, Konstantinos; Xue, Song; Alberts, Ian; Uehlinger, Dominik; Rominger, Axel; Shi, Kuangyu; Afshar-Oromieh, Ali (2023). [177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease. Journal of nuclear medicine, 64(10), pp. 1570-1573. Society of Nuclear Medicine 10.2967/jnumed.123.265577

[img] Text
jnumed.123.265577.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Download (675kB) | Request a copy

We report the dosimetric evaluation of prostate-specific membrane antigen-based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA-based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.

Item Type:

 Journal Article (Original Article)

Division/Institute:

 04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension

UniBE Contributor:

 Mercolli, Lorenzo, Mingels, Clemens, Manzini, Giulia, Cumming, Paul, Zeimpekis, Konstantinos, Xue, Song, Alberts, Ian Leigh, Uehlinger, Dominik, Rominger, Axel Oliver, Shi, Kuangyu, Afshar Oromieh, Ali

Subjects:

 600 Technology > 610 Medicine & health

ISSN:

 0161-5505

Publisher:

 Society of Nuclear Medicine

Language:

 English

Submitter:

 Pubmed Import

Date Deposited:

 25 Aug 2023 16:18

Last Modified:

 05 Oct 2023 00:14

Publisher DOI:

 10.2967/jnumed.123.265577

PubMed ID:

 37620052

Uncontrolled Keywords:

 177Lu chronic kidney disease dosimetry kidney failure prostate-specific membrane antigen radioligand therapy

BORIS DOI:

 10.48350/185725

URI:

 https://boris.unibe.ch/id/eprint/185725

Actions (login required)

Edit item Edit item
Provide Feedback